Showing 1 to 6 of 6 results
LSD Shows Promise in Treating Anxiety, Paving Way for Further Research and Potential FDA Approval
A study by Mindmed found that LSD significantly reduced anxiety symptoms in patients with generalized anxiety disorder, lasting up to three months, prompting further research and potential FDA approval.
LSD Shows Promise in Treating Anxiety, Paving Way for Further Research and Potential FDA Approval
A study by Mindmed found that LSD significantly reduced anxiety symptoms in patients with generalized anxiety disorder, lasting up to three months, prompting further research and potential FDA approval.
Progress
20% Bias Score
Health Guru Fined After Retreat Participant's Death
A Melbourne health guru, Deanne Mathews, pleaded guilty to supplying magic mushrooms at a retreat where a participant died after drinking a mushroom tonic; she received a $3000 fine, with police finding no causal link between the mushrooms and the death.
Health Guru Fined After Retreat Participant's Death
A Melbourne health guru, Deanne Mathews, pleaded guilty to supplying magic mushrooms at a retreat where a participant died after drinking a mushroom tonic; she received a $3000 fine, with police finding no causal link between the mushrooms and the death.
Progress
60% Bias Score
Colorado Springs Restricts Psychedelic Therapy Despite State Legalization
Colorado legalized therapeutic psilocybin, but Colorado Springs, home to many veterans, is restricting access to "healing centers" offering the treatment, limiting availability despite evidence of its therapeutic value for PTSD.
Colorado Springs Restricts Psychedelic Therapy Despite State Legalization
Colorado legalized therapeutic psilocybin, but Colorado Springs, home to many veterans, is restricting access to "healing centers" offering the treatment, limiting availability despite evidence of its therapeutic value for PTSD.
Progress
32% Bias Score
DEA Forwards Psilocybin Reclassification Petition to HHS
The DEA has forwarded a petition to reclassify psilocybin from Schedule I to Schedule II of the Controlled Substances Act, marking a potential shift in federal policy regarding psychedelic-assisted therapy for patients in end-of-life care after a three-and-a-half-year process, driven by evidence of ...
DEA Forwards Psilocybin Reclassification Petition to HHS
The DEA has forwarded a petition to reclassify psilocybin from Schedule I to Schedule II of the Controlled Substances Act, marking a potential shift in federal policy regarding psychedelic-assisted therapy for patients in end-of-life care after a three-and-a-half-year process, driven by evidence of ...
Progress
36% Bias Score
Psychedelic Retreat Shows Promise for PTSD Treatment, But Raises Concerns
Nine US military veterans with PTSD participated in a psychedelic retreat in Mexico using psilocybin and 5-MeO-DMT in March; eight reported significant symptom improvement, while one experienced negative effects; the Department of Veterans Affairs is conducting clinical trials to explore the potenti...
Psychedelic Retreat Shows Promise for PTSD Treatment, But Raises Concerns
Nine US military veterans with PTSD participated in a psychedelic retreat in Mexico using psilocybin and 5-MeO-DMT in March; eight reported significant symptom improvement, while one experienced negative effects; the Department of Veterans Affairs is conducting clinical trials to explore the potenti...
Progress
40% Bias Score
Daughter's Suicide Prompts Father's Journey of Grief and Healing
Freyja Lee, a 21-year-old Australian woman, died by suicide in 2019 after a prior suicide attempt; her father describes his grief, regrets, and ultimate healing process using psychedelic medicine.
Daughter's Suicide Prompts Father's Journey of Grief and Healing
Freyja Lee, a 21-year-old Australian woman, died by suicide in 2019 after a prior suicide attempt; her father describes his grief, regrets, and ultimate healing process using psychedelic medicine.
Progress
12% Bias Score
Showing 1 to 6 of 6 results